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In light of increasing national attention on the high rates of prescribing psychotropic 
medication for children in foster care, and related new federal requirements for state 
reporting to the federal government, we analyzed child welfare agency laws, policies, 
and regulations in sixteen states. Our analysis revealed that states with monitoring 
policies in place tend to use informal guidance or underdeveloped policy statements 
that were likely not subject to public notice or comment, and afforded little, if any, 
opportunity for redress. This Article argues that, given the new federal requirements 
related to psychotropic medications and children in foster care, the state policy-
making process must become more transparent to ensure broad public input and 
recourse in the case of non-compliance. 
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Introduction 
Psychotropic medications1 are prescribed to approximately one in 
five of the over 400,000 children in foster care in the United States, based 
on regional Medicaid claims analyses2—about ten times more than 
children in the general population.3 This prescribing disparity persists 
despite media attention to and policy makers’ interest in the issue.4 
 
 1. Psychotropic medications, also sometimes called psychiatric or psychotherapeutic 
medications, refer to a broad category of medications that “treat mental disorders.” Nat’l Inst. of 
Mental Health, U.S. Dep’t of Health & Human Servs., Mental Health Medications 1 (2010). 
However, individual state agencies, legislatures, or courts may separately define psychotropic 
medications in either broader or more limited terms. 
 2. Children’s Bureau, U.S. Dep’t of Health & Human Servs., Foster Care Statistics 2012, at 
1 (2013). Studies estimate that somewhere between thirteen to thirty-seven percent of children in 
foster care have been prescribed psychotropic medication. Estimates vary widely between different 
studies. Ramesh Raghavan et al., Interstate Variations in Psychotropic Medication Use Among a 
National Sample of Children in the Child Welfare System, 15 Child Maltreatment 121, 121 (2010). 
 3. Although the rates of medication for children in foster care vary widely, all studies agree that 
children in foster care are prescribed psychotropic medications at much higher rates than children in 
the general population, or even other children on Medicaid. Mark Olfson et al., National Trends in the Use 
of Psychotropic Medications by Children, 41 J. Am. Acad. Child & Adolescent Psychiatry 514, 514–21 
(2002). 
 4. A. Rachel Camp, A Mistreated Epidemic: State and Federal Failure to Adequately Regulate 
Psychotropic Medications Prescribed to Children in Foster Care, 83 Temp. L. Rev. 369, 373–75 (2011). 
Camp lists increasing media coverage as one of two key drivers for increasing state regulation of 
psychotropic medications. Id. at 374. “[G]rowing media coverage of high profile cases involving 
J - Noonan_19 (E. GOLDBERG).DOC (Do Not Delete) 8/17/2014 4:55 PM 
August 2014]      FOSTERING TRANSPARENCY 1517 
Identifying the type of monitoring policies put in place by state child 
welfare agencies to address this issue may be critical to understanding 
the lack of progress. 
Burgeoning concern about the high rates of psychotropics 
prescribed to children in foster care led the federal government to act.5 
In 2006, the Government Accountability Office (“GAO”) issued a report 
documenting the challenges facing child welfare systems, and noted that 
one in three states identified the use of psychotropic medications in their 
foster care population as among their most pressing issues to address 
over the next five years.6 In 2008, the federal government responded 
through several provisions in the Fostering Connections to Success and 
Increasing Adoptions Act (“FCA”),7 which requires states to set up a 
healthcare coordination and oversight plan for children in foster care.8 
 
children in foster care receiving psychotropic medications at . . . extremely high rates . . . has helped to 
raise awareness of the issue.” Id. (citations omitted). Overall, the rates of psychotropic medications 
remain high among children in foster care. See David Rubin et al., Interstate Variation in Trends of 
Psychotropic Medication Use Among Medicaid-Enrolled Children in Foster Care, 34 Child. & Youth 
Services Rev. 1492, 1496–97 (2012). However, some sub-populations have experienced stabilization in 
prescription rates. See Vilawan Chirdkiatgumchai et al., National Trends in Psychotropic Medication 
Use in Young Children: 1994–2009, 132 Pediatrics 615, 615–18 (2013) (discussing how rates of 
prescribing for very young children stabilized in the late 2000s). 
 5. Although this Article’s focus is psychotropic medication rates for children in foster care, the 
federal government has displayed broad concern about high rates of psychotropic medication 
prescribed to all children. For example, to rein in the high usage rates of psychotropic medications, the 
U.S. Department of Justice (“DOJ”) recently settled a suit against Johnson and Johnson (“J&J”) in 
which the DOJ alleged that J&J promoted the use of Risperdal, a psychotropic medication, to treat 
children with behavioral problems, even though it was only approved by the FDA for the treatment of 
schizophrenia, and even though they knew that Risperdal increased the risk of developing diabetes. 
Katie Thomas, J.&J. to Pay $2.2 Billion in Risperdal Settlement, N.Y. Times, Nov. 5, 2013, at B1; Tom 
Wilemon, Study: Antipsychotic Drugs Put Kids at Diabetes Risk, USA Today (Aug. 22, 2013), 
http://www.usatoday.com/story/news/nation/2013/08/21/antipsychotic-drugs-kids-diabetes/2682925/. 
 6. U.S. Gov’t Accountability Office, GAO-07-75, Child Welfare: Improving Social Service 
Program, Training, and Technical Assistance Information Would Help Address Longstanding 
Service-Level and Workforce Challenges 19 fig.7 (2006). 
 7. Fostering Connections to Success and Increasing Adoptions Act of 2008, Pub. L. No. 110-351, 
§ 205, 122 Stat. 3949, 3961 (codified as amended in scattered sections of 42 U.S.C.).  
 8. The healthcare coordination and oversight plan must be developed “in consultation with 
pediatricians, other experts in health care, and experts in and recipients of child welfare services . . . 
for the ongoing oversight and coordination of health care services for any child in a foster care 
placement, which shall ensure a coordinated strategy to identify and respond to the health care needs 
of children in foster care placements, including mental health and dental health needs.” 42 U.S.C. 
§ 622(b)(15)(A). In 2012, the Administration for Children identified five areas related to psychotropic 
medication that must be included in states’ Oversight Plan, which is part of their Annual Progress and 
Services Report. Specifically, and in coordination with the State Medicaid Agency, the Oversight Plan 
must outline the “oversight of prescription medicines, including protocols for the appropriate use and 
monitoring of psychotropic medications” including information on: (1) “[c]omprehensive and 
coordinated screening, assessment, and treatment planning mechanisms;” (2) “[i]nformed and shared 
decision-making (consent and assent) and methods for on-going communication between . . . key 
stakeholders;” (3) “[e]ffective medication monitoring at both the client and agency level;” 
(4) “[a]vailability of mental health expertise and consultation . . . (at both the agency and individual 
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The FCA increased oversight of children in foster care, which was 
reinforced through provisions of the Child and Family Services 
Improvement and Innovation Act of 2011 (“CFSIIA”).9 CFSIIA requires 
state child welfare agencies to develop a plan for the oversight of 
prescription medication, which must include protocols “for the 
appropriate use and monitoring of psychotropic medications.”10 
Several academic studies reported that by 2010, the majority of state 
child welfare agencies had or were developing policies related to the 
oversight of psychotropic medications for children in foster care.11 These 
studies examined the extent to which states were implementing 
monitoring policies related to psychotropic drugs and children in foster 
care. None of these studies identified their findings on a state-by-state 
basis, however, which made it difficult to identify the substance and 
scope of each policy. Moreover, the studies relied predominately on 
information from “key informants” at state agencies. These “key 
informants” included state child welfare and related agency staff, medical 
or mental health directors, foster care administrators, and other state 
mental health professionals and policymakers.12 Further adding to the 
difficulty of identifying the substance and scope of the oversight 
provisions, the “policies” reported in these studies included not only self-
reporting by agencies but also information obtained directly from the 
“key informants.”13 
This Article builds on the existing literature by comprehensively 
investigating the types of monitoring policies enacted by several states. 
We define monitoring policies in two ways. First, as pre-authorization 
policies, which require “physicians to obtain preapproval in order for a 
patient to receive coverage for nonpreferred, and typically more 
 
case level)”; and (5) “[m]echanisms for . . . sharing accurate and up-to-date information . . . related 
to . . . psychotropics . . . to clinicians, child welfare staff, and consumers.” Children’s Bureau, U.S. 
Dep’t of Health & Human Servs., Log No. ACYF-CB-IM-12-03, Information Memorandum 12–13 
(2012) [hereinafter Information Memorandum 12-03]. 
 9. Child and Family Services Improvement and Innovation Act of 2011, Pub. L. No. 112-34, 
§ 101(b)(2), 125 Stat. 369. 
 10. Id. at 369. 
 11. See, e.g., Laurel K. Leslie et al., Tufts Clinical & Translational Sci. Inst., Multi-state 
Study on Psychotropic Medication Oversight in Foster Care 1, 4–5 (2010); Thomas I. Mackie et al., 
Psychotropic Medication Oversight for Youth in Foster Care: A National Perspective on State Child 
Welfare Policy and Practice Guidelines, 33 Child. & Youth Services Rev. 2213, 2216–18 (2011). 
 12. Leslie et al., supra note 11, at 3; see also Medicaid Med. Dirs. Learning Network & 
Rutgers Ctr. for Educ. & Research on Mental Health Therapeutics, Antipsychotic Medication 
Use in Medicaid Children and Adolescents: Report and Resource Guide from a 16-State Study 
13 (2010). 
 13. Leslie et al., supra note 11, at 3. Relying on information provided by “key informants” can 
be problematic since they often share or report their personal perspective only, and thus may not truly 
represent the agency. See, e.g., Paula L. Grubb et al., Workplace Bullying: What Organizations Are 
Saying, 8 Emp. Rts. & Emp. Pol’y J. 407, 422 (2004) (discussing the research limitations of “key 
informant” interviewing). 
J - Noonan_19 (E. GOLDBERG).DOC (Do Not Delete) 8/17/2014 4:55 PM 
August 2014]      FOSTERING TRANSPARENCY 1519 
expensive, medications.”14 In some instances, pre-authorization may 
require court approval.15 Second, as “red flag” policies, which identify 
“[p]atterns that may signal that factors other than clinical need are 
impacting the prescription of psychotropic medications,”16 and therefore 
typically trigger a secondary review. Red flags identified by experts 
include the use of psychotropic medications for young children, 
unusually high dosage levels, and multiple medications prescribed 
simultaneously.17 Better monitoring by state child welfare agencies could, 
in theory, show that the disparity in prescription rates for children in 
foster care is somehow justified.  
Unfortunately, monitoring is a second-order problem for 
policymakers concerned about high rates of psychotropic medication 
prescription because analyzing monitoring policies is not directly related 
to curbing rates of prescription rates. More effective monitoring is 
necessary to understand whether and in what circumstances 
overprescribing occurs and the development of policies that effectively 
address the root causes of overprescribing.  
This Article makes three contributions to further the development 
and understanding of monitoring policies related to the use of 
psychotropic medications for children in foster care. First, it shows that 
informal policies are the primary tools used by states to monitor 
psychotropic medications and children in foster care—a choice that 
should be revisited. “Formal policies” either take the form of statutes, 
laws enacted by the legislature, or agency rulemaking, legislative rules 
promulgated by an administrative agency, and are legally binding.18 In 
contrast, “informal policies” are non-binding in nature and are typically 
established through guidance documents, also commonly referred to as 
non-legislative, interpretive rules, or policy statements.19 Although states 
vary considerably in terms of how they define these guidance documents, 
and whether and under what circumstances a notice and comment period 
occurs, the majority of states do not require notice or comment before 
the issuance of guidance documents.20 This is consistent with the 2010 
Model State Administrative Procedure Act (“MSAPA”).21 
 
 14. Christine Y. Lu et al., Association Between Prior Authorization for Medications and Health 
Service Use by Medicaid Patients with Bipolar Disorder, 62 Psychiatric Services 186, 186 (2011). 
 15. See, e.g., Cal. Code Regs. tit. 22, § 89475 (2014) (prohibiting caregivers from compelling 
children in California foster care to take psychotropic medication without prior authorization in the 
form of a court order). 
 16. Information Memorandum 12-03, supra note 8, at 8. 
 17. See Leslie et al., supra note 11, at 7 tbl.1. 
 18. Ronald M. Levin, Rulemaking Under the 2010 Model State Administrative Procedure Act, 
20 Widener L.J. 855, 859–61 (2011). 
 19. Id. at 856. 
 20. Rulemaking by federal agencies is subject to a single federal statute called the Administrative 
Procedure Act (“APA”). See 5 U.S.C. §§ 551–559 (2006). The federal APA does not govern states; 
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In our review, we could not locate many of the monitoring policies 
reported in the foregoing studies, suggesting the policies are not 
available in public databases or on the agencies’ websites, and were likely 
based on internal agency memorandum or were simply an articulation of 
state norms.  
Second, this Article catalogues and analyzes state policies, to the 
extent that they exist, related to the use of psychotropics in foster care. 
We show that the existing policies are underdeveloped and fail to 
consider much of the monitoring criteria that experts and state agencies 
have identified as essential to protecting children.22 Finally, although this 
Article does not settle the ongoing debate about the uses and abuses of 
informal policies, we agree with scholars who argue that the benefits of, 
and need for, more transparency increase with the severity of a rule’s 
potential effects.23 Thus, policies that materially limit individual liberty 
rights—such as the prescribing of psychotropic medications—should be 
more formal, consistent with “rule of law” values.24 
By “rule of law,” this Article refers to the legal processes for the 
creation and enforcement of, or challenges to, the formal or informal 
policies of a governmental agency.25 In this context, a rule of law 
approach would examine whether the policies were formal or informal, 
and by extension, whether they were readily available and potentially 
known to all stakeholders involved in the decisionmaking process. Here, 
 
rather each state adopts its own APA equivalent. See Appendix B for a table of states reviewed in this 
Article, their definitions of formal and informal policies, and whether notice and comment is required 
prior to the issuance of guidance documents. Note that four of the sixteen states reviewed require 
some form of notice and comment for guidance documents, though we identified relevant monitoring 
policies in only two of those four.  
 21. See Model State Admin. Procedure Act § 311(e) (2010). Under the MSAPA, an 
agency may issue a guidance document without using rulemaking procedures, however, agencies 
must follow other procedural obligations. Id. (requiring agencies to, among other things, 
maintain and publish an index of all of its effective guidance documents).  
 22. See infra Part II.B for a discussion of these underdeveloped policies that do not consider 
factors essential to protecting children, including: the use of psychotropic medication in young 
children, the dosage level, and whether multiple medications are prescribed simultaneously. Leslie et 
al., supra note 11, at 7 tbl.1. 
 23. For example, if an agency regulation seeks to deny liberty or property, the Due Process 
Clause and all of its protections will be implicated. See, e.g., U.S. Const. amend. XIV, § 1 (“[N]or shall 
any State deprive any person of life, liberty, or property, without due process of law . . . .”); Mark 
Seidenfeld, Substituting Substantive for Procedural Review of Guidance Documents, 90 Tex. L. Rev. 
331, 339 n.43 (2011) (noting that whenever liberty or property is limited by an agency order, the 
formalities and protections of the Due Process Clause are implicated). Cf. Sarah Jane Hughes, A Case 
for Regulating Cyberpayments, 51 Admin. L. Rev. 809, 832 (1999) (noting that transparency is even 
more important where consumers must evaluate competing choices and risks). 
 24. Thomas O. Sargentich, The Future of Administrative Law, 104 Harv. L. Rev. 769, 774 (1991) 
(book review) [hereinafter Sargentich, Future of Administrative Law]. 
 25. See infra Part III for a detailed discussion of this “rule of law” approach to policymaking and 
the need for transparency in the rulemaking process. 
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stakeholders include caseworkers, parents, foster parents, and youth. 
Moreover, most child welfare systems rely on external medical personnel 
and health systems to provide health and behavioral care.26 Increased 
transparency surrounding the development and implementation of these 
policies would promote efficiency and uniformity among and across 
providers. Policies pertaining to the use of psychotropic medications for 
children in state custody affect the liberty and well being of children, the 
majority of whom cannot consent or object to the use of these 
medications.27 Therefore, this Article concludes that states should 
consider adopting formal policies consistent with rule of law values, 
especially to the extent that informal policies are not resulting in targeted 
changes in prescribing rates. 
This Article proceeds in four Parts. Part I reviews the child welfare 
system and specific healthcare challenges for children in the system, 
focusing on psychotropic medications. Part II examines federal and state 
actions intended to increase oversight of psychotropic medications; it 
also reviews the development of federal and state requirements, where 
overall action has been slow and difficult to document. Part III 
summarizes the principles of transparency and discusses the rule of law 
approach to policymaking. Finally, Part IV applies rule of law principles 
to policymaking related to psychotropic medications and children in 
foster care, and argues that greater transparency is needed. 
I.  Background: Children in Child Welfare Systems 
“Child welfare systems” are the agencies responsible for a child’s 
health and well-being when the child is removed from the care of their 
parent or legal guardian as the result of abuse or neglect.28 For the 
 
 26. See Camp, supra note 4, at 397–401 (describing the consent process and some of the 
fragmentation and administrative issues with obtaining healthcare for children in foster care). 
 27. Some states allow youth to consent for medical treatment before the age of 18. See, e.g., 55 
Pa. Code § 3680.52(6) (2013) (“[A] child who is 14 years of age or older shall consent to mental health 
treatment, including the administration of psychotropic medication.”). 
 28. The federal law in effect in 2003 defined “child abuse and neglect” as meeting a minimal 
standard of “any recent act or failure to act on the part of a parent or caretaker, which results in death, 
serious physical or emotional harm, sexual abuse or exploitation, or an act or failure to act which 
presents an imminent risk of serious harm.” Child Abuse Prevention and Treatment and Adoption 
Reform Act, 42 U.S.C. § 5106g(2) (2003); see Gerard F. Glynn, The Child’s Representation Under 
CAPTA: It Is Time for Enforcement, 6 Nev. L.J. 1250, 1250–53 (2006) (providing background and 
overview of Child Abuse Prevention and Treatment and Adoption Reform Act (“CAPTA”)). 
CAPTA was first passed in 1974 to permit states to allocate federal funds toward combatting child 
abuse. Caroline T. Trost, Chilling Child Abuse Reporting: Rethinking the CAPTA Amendments, 
51 Vand. L. Rev. 183, 192 (1998). Under two doctrines—parens patriae and the “best interest of the 
child” standard—the responsibility of the state in protecting children has evolved. See id. at 190, 191 & 
nn. 38–39, 194–200 (discussing both standards and the history of the state’s role in child abuse 
enforcement). Child abuse and neglect are defined by state law, although states accepting federal 
funding to combat child abuse and neglect must meet the federal benchmark as defined in CAPTA. 
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purposes of this Article, ‘children in foster care’ refers to children in out-
of-home placements within child welfare systems.29 This Part describes 
some of the key organizational features of child welfare systems, the 
behavioral needs of the children for whom they care, and current trends 
in psychotropic medication usage by children in foster care. 
A. State Child Welfare Systems and the Problem of Fragmentation 
Although state welfare agencies are responsible for ensuring that 
children in their care obtain healthcare, including psychotropic 
medications, they also face challenges for effectively delivering care.30 
For example, state child welfare system structures differ in organizational 
design, resulting in widespread variation in how policies are 
implemented.31 Under recent federal legislation,32 child welfare agencies 
are responsible for implementing new state protocols directed at 
 
Admin. for Children & Families, U.S. Dep’t of Health & Human Servs., State Definitions of Child 
Abuse and Neglect, Child Welfare Info. Gateway, https://www.childwelfare.gov/can/defining/ 
state.cfm (last visited Aug. 1, 2014). States then enforce their child abuse statutes through their 
respective Child Protective Services (“CPS”), unique agencies designed with the purpose of preserving 
the family unit when possible. See Admin. for Children & Families, U.S. Dep’t of Health & Human 
Servs., Family Reunification, Child Welfare Info. Gateway, https://www.childwelfare.gov/ 
permanency/reunification (last visited Aug. 1, 2014). Concomitant or separate civil and/or criminal 
liability may attach to the CPS investigation. Admin. for Children & Families, U.S. Dep’t of Health 
& Human Servs., The Court System and Child Abuse and Neglect, Child Welfare Info. Gateway, 
https://www.childwelfare.gov/pubs/usermanuals/courts_92/courtsc.cfm (last visited Aug. 1, 2014). 
 29. Children in “out-of-home placement” have been removed from their home by the child 
welfare system as a result of parental abuse or neglect. Children are subsequently placed in either an 
institutionalized care setting or with a foster family. See Michael Wald, State Intervention on Behalf of 
“Neglected” Children: A Search for Realistic Standards, 27 Stan. L. Rev. 985, 989 n.21 (1975) 
(discussing out-of-home placement as a potentially coercive aspect of foster care). 
 30. Laws passed to improve oversight of psychotropic medications have focused on child welfare 
agencies as responsible for monitoring progress (to be discussed infra Part II) and, when necessary, 
collaborating with other agencies such as Medicaid. In regard to implementing the FCA, “[s]tate and 
Tribal agencies are required to develop a plan for ongoing oversight and coordination of health care 
services for children in foster care, including mental health and dental health needs, in coordination 
with the State Medicaid agency, pediatricians, general practitioners, and specialists.” Children’s 
Bureau, U.S. Dep’t of Health & Human Servs., Log No. ACYF-CB-PI-10-11, Program Instruction 
21 (2010) [hereinafter Program Instructions 10-11]. 
 31. Child welfare agencies provide services through fundamentally different approaches, 
depending on whether they are supervised at the state or county level (also known as being county-
administered or state-administered). See Rebecca Wells, Managing Child Welfare Agencies: What Do 
We Know About What Works?, 28 Child. & Youth Services Rev. 1181, 1186 (2006) (discussing 
different types of child welfare systems and characteristics that matter for administering services). In 
addition, child welfare systems may be administered either directly through state or county services, or 
through a contractor. Id. County administered states—California, Colorado, Minnesota, New York, 
North Carolina, North Dakota, Pennsylvania, Ohio, and Virginia—also have some of the largest 
populations of children in the system. Three other states—Maryland, Nevada, and Wisconsin—are 
considered to have a hybrid administration. Children’s Bureau, U.S. Dep’t of Health & Human 
Servs., State vs. County Administration of Child Welfare Services 12 (2012). 
 32. See supra notes 7–10 and accompanying text for a discussion of federal law mandating that child 
welfare agencies implement new state protocols for improving healthcare for children in foster care. 
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improving healthcare for children in foster care, though the actual 
process for getting healthcare to such children involves many additional 
players and is highly fragmented. 
The involvement of both Medicaid and managed care organizations 
(“MCOs”) is essential to the effective oversight of psychotropic 
medication use by children in foster care.33 Typically, children in foster 
care receive their health insurance through Medicaid.34 As such, each 
state’s Medicaid agency plays an integral role in setting policies and 
overseeing the healthcare of children in foster care.35 Although Medicaid 
is a federal program that entitles children covered by it to certain 
diagnostic and screening treatments36 along with other care, many of the 
coverage details are left to the discretion of the individual states, such as 
the type of non-pharmacological therapeutic interventions reimbursed 
through Medicaid. In states that use private insurance companies, or 
“payers,” to provide Medicaid,37 the Medicaid agency contracts with the 
private payers (typically MCOs).38 
Children in the child welfare system often experience inconsistency 
in access and treatment from physical health and behavioral health 
 
 33. In some instances, children in foster care have their medical care paid for directly through the 
Medicaid agency in a system known as Fee For Service. See, e.g., Melinda Dutton et al., Medicaid 
Managed Care for Children in Foster Care 11 (2013), available at http://www.uhfnyc.org/ 
assets/1072 (identifying Medicaid “fee for service” reimbursement as an option for foster care agencies 
in New York). However, as of 2010, thirty-five states had adopted Medicaid managed care programs 
for their foster care populations. Kamala D. Allen et al., Medicaid and Children in Foster Care 3 
(2013), available at http://childwelfaresparc.files.wordpress.com/2013/ 
03/medicaid-and-children-in-foster-care.pdf. Managed care organizations (MCOs) are a type of health 
insurance organization. Managed Care, MedlinePlus, http://www.nlm.nih.gov/medlineplus/ 
managedcare.html (last visited Aug. 1, 2014). MCOs have contracts with healthcare providers and 
medical facilities to provide care for members at reduced costs and include health maintenance 
organizations (“HMOs”) and preferred provider organizations (“PPOs”). Id. For more information 
about MCOs, see Barry R. Furrow, Managed Care Organizations and Patient Injury: Rethinking 
Liability, 31 Ga. L. Rev. 419, 421–27 (1997). 
 34. Kamala D. Allen & Taylor Hendricks, Ctr. for Health Care Strategies, Medicaid and 
Children in Foster Care 1 (2013). 
 35. See Kamala D. Allen et al., Ctr. for Health Care Strategies, Inc., Improving Outcomes 
for Children in Child Welfare: A Medicaid Managed Care Toolkit 7 (2012). 
 36. This Medicaid screening and diagnosis federal entitlement benefit is known as “early and 
periodic screening, diagnostic, and treatment services” (“EPSDT”), and is mandated nationally. 42 
U.S.C. §§ 1396a(a)(10)(A), 1396a(a)(43), 1396d(a)(4)(B), 1396d(r) (2011). 
 37. State MCO arrangements and other types of utilization controls are incredibly complex. 
However, about half of all states use MCOs to administer large portions of their Medicaid program. A 
2012 Government Accountability Office (“GAO”) study found twelve states to be “MCO 
predominant” and sixteen states to be “above average” in their use of MCOs. U.S. Gov’t 
Accountability Office, GAO-12-872R, Medicaid: States’ Use of Managed Care 5 fig.1 (2012). 
 38. See id. at 1 (“[W]hile states commonly contract with managed care organizations (MCO) to 
provide the full range of covered Medicaid services to certain enrollees, they also frequently rely on 
other arrangements, such as limited benefit plans, which provide a limited set of services, such as 
dental care or behavioral health services, or primary care case management (PCCM) programs . . . .”) 
(citations omitted). 
J - Noonan_19 (E. GOLDBERG).DOC (Do Not Delete) 8/17/2014 4:55 PM 
1524 HASTINGS LAW JOURNAL [Vol. 65:1515 
providers for a number of reasons, including removal to foster care 
placement that is not near their home or doctor of origin, or due to 
multiple placement moves while in foster care.39 Moreover, children 
placed in residential treatment centers, which represent ten percent of all 
children in foster care nationally,40 may be required to see the healthcare 
providers that work for, or contract with, the agency with whom they 
have been placed. And although enrollment in Medicaid means access to 
the enforceable “early and periodic screening, diagnostic, and treatment 
services” entitlements,41 it also means that the child may face a lack of 
coordinated care and provider consistency if they were not previously 
enrolled in Medicaid, or if they reunify with their non-Medicaid eligible 
family in the future. 
Additionally, obtaining healthcare for children in foster care can 
mean navigating complex consent procedures in many states. Except for 
emergencies, a child too young to consent for her own medical care still 
needs consent from her parent or guardian.42 When the state removes the 
child from her home, the responsibility of consenting for medical care 
may shift.43 State laws dictate who may provide consent for children’s 
medical care when they are removed from their parents’ custody. 
Broadly speaking, these laws either dictate that biological parents 
maintain responsibility for consenting for a child’s medical care, or that 
the power to consent shifts to another entity or individual—typically, the 
state, foster care agency, or family court with jurisdiction.44 In many 
states, this determination is not simple or straightforward. Consent is 
further complicated as children become adolescents,45 although most 
states have a bright-line cutoff at which children are assumed old enough 
to consent to their own medical care.46 Finally, although courts may 
 
 39. See Ramesh Raghavan et al., A Preliminary Analysis of the Receipt of Mental Health 
Services Consistent with National Standards Among Children in the Child Welfare System, 100 Am. J. 
Pub. Health 742, 745–47 (2010) (finding that less than ten percent of children in child welfare obtain 
mental healthcare consistent with national standards, and discussing the reasons for care inconsistent 
with national standards). 
 40. Id. at 747. 
 41. For more information about the EPSDT entitlement, see supra note 36 and accompanying text. 
 42. See, e.g., Bellotti v. Baird, 443 U.S. 622, 640 (1979) (noting that “immature minors often lack 
the ability to make fully informed choices that take account of both immediate and long-range 
consequences”); Cardwell v. Bechtol, 724 S.W.2d 739, 749 (Tenn. 1987) (discussing the “general rule” 
that parental consent is required for medical treatment of minors). 
 43. States clearly define what rights transfer from the child’s biological parents and legal 
guardians. See Camp, supra note 4, at 397–401. 
 44. See id. (summarizing several states’ consent procedures for children in child welfare and 
demonstrating how the person or entity responsible provides consent). 
 45. See generally Rhonda Gay Hartman, Coming of Age: Devising Legislation for Adolescent 
Medical Decision-Making, 28 Am. L.J. & Med. 409 (2002) (discussing the difficulties and challenges of 
adolescent consent policies). 
 46. See, e.g., N.Y. Pub. Health Law § 2504(1) (McKinney 2005) (permitting any person who is 
eighteen years of age or older to consent to routine medical treatment); Colo. Rev. Stat. Ann. § 13-
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recognize the right to decline medical care within the power to consent, 
the ability of children in foster care to refuse care is not well understood.47 
B. The Children and Youth in Foster Care 
As of September 2012, there were about 400,000 children in the U.S. 
foster care system.48 This is a low number in the modern era of child 
welfare, which is largely attributed to a concerted effort to increase rates 
of adoption, divert children from foster care by increasing in-home 
support, and utilize a more sophisticated response system to allegations 
of abuse and neglect.49 The current population of children in foster care 
includes a large number of very young children and a large number of 
teenagers, particularly sixteen- and seventeen-year-olds.50 These two 
groups of children tend to have different mental health needs and 
require access to other types of services than children outside of the 
foster care system. 
It is well documented that children in foster care experience higher 
rates of trauma, increased mental health needs, and higher healthcare 
needs than children in the general population.51 One recent study 
estimated that around seventy percent of children in foster care had 
experienced “complex trauma”—trauma deemed particularly harmful 
 
22-103(1) (2013) (permitting any person eighteen years of age or older, or any minor fifteen years of 
age or older—who has met specific statutory requirements—to consent to routine medical treatment); 
see Hartman, supra note 45, at 420–22 (discussing the different approaches states have taken to 
determine when minors are of sufficient age to provide their own consent to medical treatment). 
 47. Without clear policies around consent and informed consent, the child’s actual ability to 
consent or refuse consent is unclear and typically, undocumented. For additional information about 
the differences between required consent of adults and minors, see generally Bellotti, 443 U.S. 622. 
 48. Children’s Bureau, U.S. Dep’t of Health & Human Servs., Foster Care Statistics 2012 1 
(2013). Since the early 2000s, there has been a 23.7% decrease in the overall number of children in 
foster care, from 523,616 in 2002 to 399,546 in 2012. The decrease in the total number of children in 
foster care is also correlated with a shift in children who populate the system. Admin. for Children & 
Families, U.S. Dep’t of Health & Human Servs., Recent Demographic Trends in Foster Care 1 
tbl.1 (2013). The most dramatic decrease was among African American children, with a decrease of 
47.1% in foster care. Id. While a remarkable reduction over the course of ten years, about one-third of 
that change was driven by California’s reduction of children in foster care by nearly 40,000 children. 
Id. at 3 fig.2. Although there was a clear trend toward reducing the number of children in foster care 
during that time period, about one-fifth of states maintained nearly the same population and a 
separate one-fifth increased the number of children in foster care. See id.  
 49. See Children’s Bureau, U.S. Dep’t of Health & Human Servs., The AFCARS Report 1 
(2013) (listing case plan goals, which include reunification, adoption, and guardianship). See generally 
Child Welfare Info. Gateway, U.S. Dep’t of Health & Human Servs., Differential Response to 
Reports of Child Abuse and Neglect (2008) (discussing new types of “differential response 
systems” and how they have benefited the foster care system). 
 50. The AFCARS Report, supra note 49, at 1 (noting that sixteen- and seventeen-year-olds 
account for fourteen percent of all children in foster care, ages one to twenty). 
 51. See, e.g., John A. Landsverk et al., Mental Health Care for Children and Adolescents 
in Foster Care: Review of Research Literature 13–19 (2006). 
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and perpetrated by a caregiver at a young age.52 For some of those 
children with serious mental health diagnoses, psychotropic medications 
may be clinically indicated as an appropriate course of treatment. 
However, research shows that children with serious mental health 
diagnoses are not the main drivers of increasing prescriptions for 
antipsychotics.53 On the contrary, the high rates of psychotropic 
medication prescription are often associated with a diagnosis of 
Attention Deficit Hyperactivity Disorder (“ADHD”).54 For instance, 
one study found that ADHD without an accompanying serious second 
disorder (such as bipolar disorder, schizophrenia, or autism) was the 
reason that one-third of all youth on Medicaid receive antipsychotic 
medication.55 
C. Psychotropic Medications and Children in Foster Care 
Psychotropic medication rates for children in foster care have 
increased dramatically in recent years.56 From 1997 to 2007, psychotropic 
medication prescription rates among all children in the United States 
increased six hundred percent.57 While rates among children in Medicaid 
are higher than the general population,58 rates among children in foster 
care are an additional three to five times greater.59 In addition to being at 
risk for greater use of psychotropic medications generally, children in 
foster care also receive multiple psychotropic medications at higher rates. 
 
 52. Johanna K.P. Greeson et al., Complex Trauma and Mental Health in Children and 
Adolescents Placed in Foster Care: Findings from the National Child Traumatic Stress Network, 
90 Child Welfare 91, 9293 (2011). 
 53. According to one study that looked at rates of use of psychotropic medications among 
children receiving public health insurance, “[a]ntipsychotics have been used concomitantly for adults 
with schizophrenia, but the rare prevalence among youths is not an explanation for the observed 
patterns. The data reveal that youths receive antipsychotics concomitantly primarily for conduct 
disorders.” Susan dosReis et al., Antipsychotic Treatment Among Youth in Foster Care, 
128 Pediatrics e1459, e146364 (2011) (describing how antipsychotics—a class of psychotropic 
medications—are used to treat less serious clinical diagnoses). 
 54. Id. at e1462 (describing how the driving diagnosis of psychotropic medications among 
children in foster care was ADHD, which accounted for 46.5% of diagnoses). 
 55. Stephen Crystal et al., Broadened Use of Atypical Antipsychotics: Safety, Effectiveness, and 
Policy Challenges, 28 Health Aff. w770, w773 (2009). 
 56. See Angela Olivia Burton, “They Use It Like Candy”: How the Prescription of Psychotropic 
Drugs to State-Involved Children Violates International Law, 35 Brook. J. Int’l L. 453, 476–77 (2010) 
(exploring the explosive growth of the use of psychotropic medications in recent decades). 
 57. See Camp, supra note 4, at 373 (“Between 1997 and 2007, the use of psychotropic medications 
by children in the general population increased sixfold.”). 
 58. See Crystal et al., supra note 55, at w774 exhibit 3 (describing how rates of atypical 
antipsychotics were about four times higher among Medicaid enrolled youth compared with privately 
ensured youth). 
 59. The widely varying estimates reflect the varying types of research conducted to investigate 
rates of usage among children in foster care. For a summary of the existing literature, see generally 
U.S. Gov’t Accountability Office, GAO-12-270T, Foster Children HHS Guidance Could Help 
States Improve Oversight of Psychotropic Prescriptions (2011). 
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One study found that over twenty percent of children in foster care who 
were prescribed psychotropic medications were taking three or more 
psychotropic medications.60 
Nearly all psychotropic medications prescribed to children are 
prescribed “off-label,” meaning that the drug is used in a way that has 
not been studied or approved by the federal agency responsible for 
oversight, the Food and Drug Administration (“FDA”).61 However, 
prescribing off-label is widely accepted within the medical community.62 
Some off-label prescribing is perceived as necessary because the FDA 
“on-label” use is announced only once extensive trials and testing have 
concluded. Historically, testing of many medications on children was not 
permitted, meaning that an FDA-approved use for a pediatric population 
simply did not exist.63 Within an outpatient pediatric setting, over sixty-
two percent of prescription visits resulted in off-label prescriptions.64 
Among some specialists, rates were higher than ninety percent.65 
Although off-label use of medication is widely accepted,66 the side 
effects of medications on children are often poorly understood because 
they have historically not been widely studied. As a result, there are 
relatively few well-documented studies on the effects of psychotropic 
 
 60. This number represents children being treated at community mental health centers, but does 
not include inpatient treatment rates, which were much higher. Daniel J. Safer et al., Concomitant 
Psychotropic Medication for Youths, 160 Am. J. Psychiatry 438, 438, 442–43 (2003). 
 61. Michelle L. Mello, Note, Psychotropic Medication and Foster Care Children: A Prescription 
for State Oversight, 85 S. Calif. L. Rev. 395, 406–07 (2012) (citing Blain v. Smithkline Beecham Corp., 
240 F.R.D. 179, 182 (E.D. Pa. 2007)). 
 62. Off-label prescribing of psychotropic medications for children is widely documented. See, e.g., 
Julie Magno Zito et al., Trends in the Prescribing of Psychotropic Medications to Preschoolers, 
283 J. Am. Med. Ass’n 1025, 1025–28 (2000) (describing widespread off-label use, particularly among 
young children); Am. Acad. of Adolescent & Child Psychiatry, A Guide for Community Child 
Serving Agencies on Psychotropic Medications for Children and Adolescents 11 (2012) 
(“Medication used in the treatment of youth with mental illnesses is often used ‘off-label,’ as is 
frequently the case in the medication treatment of pediatric physical illness. There are many 
medications approved for adults that are used off-label for youth. Off-label prescribing is very 
common . . . .”). 
 63. Drug Research and Children, U.S. Food & Drug Admin., 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143565.htm (last updated Aug. 24, 2011) 
(According to the FDA, “[m]ost drugs prescribed for children have not been tested in children. Before 
the Food and Drug Administration initiated a pediatric program, only about twenty percent of drugs 
approved by the FDA were labeled for pediatric use. By necessity, doctors have routinely given drugs 
to children ‘off label,’ which means the drug has not been approved for use in children based on the 
demonstration of safety and efficacy in adequate, well-controlled clinical trials.”). Despite being 
common practice, prescribing off-label remains problematic. One study noted that “[c]oncern about 
this age group relates to off-label (unlabeled) use, i.e., for treatment indications with little or no 
proven efficacy and lacking product package insert labeling information approved by the U.S. Food 
and Drug Administration.” Zito, supra note 62, at 1025. 
 64. Alicia T. F. Bazzano et al., Off-Label Prescribing to Children in the United States Outpatient 
Setting, 9 Acad. Pediatrics 81, 83 (2009). 
 65. See id. 
 66. Camp, supra note 4, at 379. 
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medications on children. Over the last decade, this has changed as 
experts have begun to document the impact of increased use of 
psychotropic medications on children. Researchers have found increasing 
evidence of serious side effects of psychotropic medications on 
children.67 Much of the research has focused on second-generation 
antipsychotics (“SGAs”), a commonly prescribed subset of psychotropic 
medications.68 Many of the identified negative side effects of SGAs have 
been linked to metabolic disorders.69 For example, one study found 
associations with significant weight gain for all antipsychotics studied and 
other serious metabolic changes in some of the antipsychotics studied.70 
Other research also concludes that SGAs increase the risk of obesity, 
Type 2 diabetes, cardiovascular conditions, and hypotension.71 Those 
risks increase with exposure to multiple medications.72 Thus, although 
largely unstudied, side effects of psychotropic medications for children 
appear serious, providing another reason to seek alternate treatment 
when possible. 
Faced with the challenge of regulating psychotropic medications, the 
federal government and child welfare agencies have instituted a series of 
reforms, which are summarized in the next Part. 
II.  Federal Requirements and State Actions Related to 
Psychotropic Medication Oversight 
Given the high stakes, both the federal government and, to a much 
lesser extent states, have begun to develop rules about how to monitor 
the use of psychotropic medications in the child welfare system. 
Although the federal government has drawn increasing attention to the 
need for effective monitoring systems, states seem reluctant to 
promulgate oversight policies. 
 
 67. See, e.g., Burton, supra note 56, at 467 (discussing the side effects of psychotropic medication 
use in children, ranging from fairly minor ones, such as dry mouth and headaches, to more severe side 
effects, including thyroid dysfunction, growth retardation, heart failure, and death). 
 68. The existing literature focuses largely on antipsychotics, and specifically SGAs. One reason is 
that much of the increased use of psychotropic medications among youth in foster care is due to 
increased prescribing of SGAs, and SGAs also have greater risk of causing metabolic health problems 
in children. See dosReis et al., supra note 53, at e1460 (citing Christoph U. Correll, Multiple 
Antipsychotic Use Associated With Metabolic and Cardiovascular Adverse Events in Children and 
Adolescents, 12 Evid. Based Mental Health 93 (2009)). 
 69. Id. 
 70. Christoph U. Correll et al., Cardiometabolic Risk of Second-Generation Antipsychotic Medications 
During First-Time Use in Children and Adolescents, 302 J. Am. Med. Ass’n 1765, 1768–70 (2009). 
 71. Roger S. McIntyre & Jeanette M. Jerrell, Metabolic and Cardiovascular Adverse Events 
Associated with Antipsychotic Treatment in Children and Adolescents, 162 Archives of Pediatric 
Adolescent Med. 929, 931–34 (2008). 
 72. Id. 
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A. Federal Requirements 
The FCA73 was enacted to improve child welfare systems, including 
broadly strengthening healthcare services for children in foster care.74 
While the FCA did not explicitly address psychotropic medications, it did 
introduce provisions meant to improve health and mental health 
oversight, which was interpreted by the Children’s Bureau in subsequent 
guidance to require states to report on psychotropic medication oversight 
policies.75 The FCA directs states to develop “a plan for the ongoing 
oversight and coordination of health care services for any child in a foster 
care placement, which shall ensure a coordinated strategy to identify and 
respond to the health care needs of children in foster care placements, 
including mental health and dental health needs.”76 
The statute goes on to describe the specific information that must be 
included in a state’s plan for oversight and coordination of healthcare 
services.77 In their reports to the federal government, states must provide 
information on “initial and follow-up health screenings” for children in 
foster care, describe “how health needs identified through screenings will 
be monitored and treated,” report on the sharing of medical information 
for children in foster care, outline “steps to ensure continuity of health 
care services,” detail the state’s approach to “the oversight of 
prescription medicines,” and report on “how the State actively consults 
with and involves physicians or other appropriate medical or non-
medical professionals in assessing the health and well being of children in 
foster care and in determining appropriate medical treatment for the 
children.”78 Additionally, state child welfare agencies must indicate “how 
health care experts were selected and how they and the Medicaid agency 
 
 73. Fostering Connections to Success and Increasing Adoptions Act of 2008 (“FCA”), Pub. L. 
No. 110-351, § 205, 122 Stat. 3949, 3961 (codified as amended in scattered sections of 42 U.S.C.). 
 74. Widely lauded by child advocacy groups, the legislation was designed to “improve critical 
education and health care services for children in foster care and better prepare older youth for 
adulthood by extending federal support for transition programs to age twenty-one.” Casey Family 
Programs, Fostering Connections to Success and Increasing Adoptions Act 1 (2009). 
 75. See infra notes 80–90 and accompanying text for a discussion of subsequent agency guidance. 
 76. FCA, § 205. 
 77. Subsequent guidance integrated the health oversight and coordination reporting into broader 
requirements that states must submit to the federal government. Every five years, states are required 
to submit a “five-year strategic plan that sets forth the vision and the goals to strengthen the States’ 
overall child welfare system” called a Child and Family Services Plan (“CFSP”). Children’s Bureau, 
U.S. Dep’t of Health & Human Servs., Log No. ACYF-CB-PI-10-09, Program Instruction 2 (2010). 
The Annual Progress and Service Reports (“APSRs”) are annual updates that states create to 
document their progress toward reaching the goals laid out in their CFSPs. Id. at 2–3. States were 
directed by guidance issued in 2010 to include an update on the progress toward the oversight and 
coordination requirements in the FCA for children in foster care. Id. States that indicated legislation 
was necessary to carry out the requirements of the FCA were required to provide the federal 
government with an update on legislative progress. Id. at 8–9. 
 78. FCA, § 205.  
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were involved in developing the health care oversight and coordination 
plan.”79 
The Children’s Bureau’s (“CB”)80 2008 Program Instruction 
(“PI”)81 to states instructing them on how to implement the newly 
enacted FCA indicated that the requirement for the state’s healthcare 
oversight and coordination plan was effective immediately.82 Subsequent 
PIs issued by the CB emphasized the agency’s concern about 
psychotropic medication oversight. In 2009, for example, the agency 
noted that “CB encourages States to pay particular attention to oversight 
of the use of psychotropic medications in treating the mental health care 
needs of children” in their plans for responding to children’s mental 
health needs and prescription medication oversight.83 Following the 
enactment of the Patient Protection and Affordable Care Act 
(“ACA”),84 the CB issued another PI for implementing the FCA, 
reiterating the need for “particular attention” to the oversight of 
psychotropic medications.85 
 
 79. Program Instructions 10–11, supra note 30, at 21. 
 80. The CB is an agency within the U.S. Department of Health and Human Services responsible for 
improving the health of children and families. What We Do, Children’s Bureau, U.S. Dep’t of Health 
& Human Servs., http://www.acf.hhs.gov/programs/cb/about/what-we-do (last visited Aug. 1, 2014). The 
statutory duties of the CB are to “investigate and report to the Secretary of Health and Human Services, 
upon all matters pertaining to the welfare of children and child life among all classes of our people, and 
[to] especially investigate the questions of infant mortality, the birth rate, orphanage, juvenile courts, 
desertion, dangerous occupations, accidents and diseases of children, employment, [and] legislation 
affecting children in the several States and Territories.” 42 U.S.C. § 192 (2011). 
 81. The majority of the regulatory or policy guidance related to the FCA is described as Program 
Instruction (“PI”) by the CB. According to the CB’s website, PIs “explain procedures and methods for 
operationalizing program policies, add details to program regulations or policy guide requirements, and 
convey to grantees program guidance information on actions they are expected or required to take.” 
Program Instructions (PI), Admin. for Children & Families, U.S. Dep’t of Health & Human Servs., 
http://www.acf.hhs.gov/programs/cb/laws-policies/program-instructions (last visited Aug. 1, 2014). 
 82. Children’s Bureau, U.S. Dep’t of Health & Human Servs., Log No. ACYF-CB-PI-08-05, 
Program Instruction 8–9 (2008). Although not discussed in this paper, similar requirements were 
placed upon federally recognized Indian tribes to implement oversight processes for children in their 
child welfare systems. Id. at 6–7. Further, the CB also identified the issue of psychotropic medications 
as a key concern and noted in a 2009 guidance that “CB encourages Tribes to pay particular attention 
to the oversight of the use of psychotropic medicines.” Children’s Bureau, U.S. Dep’t of Health & 
Human Servs., Log No. ACYF-CB-PI-09-07, Program Instruction 10 (2009). Most relevant to the 
monitoring of psychotropic medications, in 2012, a notice was published in the Federal Register 
announcing a federal grant to “announce the award of a single-source program expansion supplement 
grant to the Tribal Law and Policy Institute in West Hollywood, CA, to support technical assistance to 
Tribes in the development of oversight plans for prescription medicines for children in Tribal foster 
care systems.” Announcement of the Award of a Single-Source Program Expansion Supplement Grant to 
the Tribal Law and Policy Institute in West Hollywood, CA, 77 Fed. Reg. 65,196 (Oct. 25, 2012). 
 83. Children’s Bureau, U.S. Dep’t of Health & Human Servs., Log No. ACYF-CB-PI-09-06, 
Program Instruction 10-11 (2009). 
 84. See Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010) 
(codified as amended in scattered sections of 25, 26, and 42 U.S.C.). 
 85. Program Instructions 10-11, supra note 30, at 21. 
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Over a short time period, the CB’s guidance to states on 
psychotropic medications evolved from a general charge to improve 
prescription drug oversight to an explicit requirement that states develop 
more robust psychotropic medication policies. In 2011, the provisions 
introduced by the FCA were amended by the CFSIIA.86 The CFSIIA 
introduced a number of updates to the FCA and included language 
directly discussing psychotropic medications: under the CFSIIA, states 
are now required to include “protocols for the appropriate use and 
monitoring of psychotropic medications” in their Annual Progress and 
Service Reports (“ASPRS”).87 
In 2012, the CB issued some of its most direct language on state 
obligations to report on psychotropic medications, noting in a guidance 
document: 
The [CFSIIA] also requires States to submit as part of the health care 
oversight plans a description of the protocols in place or planned to 
oversee and monitor the use of psychotropic medications among 
children in foster care . . . . As States develop their plans for 
prescription psychotropic medication management, there is also work 
to be done to identify effective psychosocial interventions that can 
improve behavioral and mental health outcomes of children receiving 
child welfare services.88 
Around the same time, the CB also issued an Information Memorandum 
solely addressing the issue of psychotropic medications, and presenting a 
comprehensive summary of research on psychotropic medications.89 
Later that same year, the CB and other federal agencies co-hosted a 
multi-day convention of child welfare experts, researchers, practitioners, 
state leaders in child welfare agencies, state Medicaid agencies, and state 
mental health agencies, with the purpose of “[c]reating and 
 
 86. See generally Child and Family Services Improvement and Innovation Act, Pub. L. No. 112-
34, 125 Stat. 369 (2011) (codified as amended in scattered sections of 42 U.S.C.). 
 87. Id. § 101(b)(2) (codified at 42 U.S.C. § 422(b)(15)(A)(v)). This section was implemented to 
the states through an Information Memo (“IM”). See generally Children’s Bureau, U.S. Dep’t of 
Health & Human Servs., Log No. ACYF-CB-IM-11-06, Information Memorandum (2011) 
(summarizing many of the provisions in the CFSIIA). IMs “are the Children’s Bureau’s primary 
means for communicating with grantees or potential grantees on a variety of matters, such as program 
activities and priorities, progress reports, research findings, available funds, related regulations, and 
proposed and pending federal legislation affecting human services programs.” Policy/Program 
Issuances, Admin. for Children & Families, U.S. Dep’t of Health & Human Servs., 
http://www.acf.hhs.gov/programs/cb/laws-policies/policy-program-issuances (last visited Aug. 1, 2014). 
In contrast, the other type of guidance that the CB commonly issues related to psychotropic 
medications are “Program Instructions,” described as issuances to “clarify and explain procedures and 
methods for operationalizing program policies, add details to program regulations or policy guide 
requirements, and convey to grantees program guidance information on actions they are expected or 
required to take.” Id. 
 88. Children’s Bureau, U.S. Dep’t of Health & Human Servs., Log No. ACYF-CB-IM-12-04, 
Information Memorandum 7 (2012). 
 89. See generally Information Memorandum 12-03, supra note 8 (discussing issues surrounding 
psychotropic medication use by children in foster care). 
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implementing integrated oversight and monitoring protocols that ensure 
the appropriate use of psychotropic medications for children in foster 
care, [which] require[s] thoughtful collaboration across complex 
systems.”90 
In addition to these requirements, several federal class action 
lawsuits against state child welfare agencies resulted in settlements that 
required improved state oversight.91 These lawsuits alleged agency-wide 
failures to oversee adequate physical and mental healthcare needs of 
children in foster care, including psychotropic medication monitoring. In 
2000, for example, Tennessee officials were sued over allegations of 
“systemic failure . . . to fulfill their legal obligations” to children in foster 
care, including mental and physical healthcare obligations.92 The 
settlement agreement in the Tennessee suit included explicit 
requirements related to the state’s oversight of psychotropic medications, 
including that the agency, “[w]ithin six months . . . shall undertake a 
review of the policies and procedures surrounding the use of 
psychotropic medications,” and that regional health nurses submit logs of 
psychotropic medication approvals to the agency’s Medical Director.93 
B. States’ (In-)Action 
Although the federal government and private litigants have sought 
to improve oversight of the use of psychotropic medications, state action 
in this area has been mixed at best. Given that several academic reports 
found that as of 2010 the majority of states had or were developing 
policies to implement federal psychotropic medication mandates,94 we 
were interested in a more in-depth review of state requirements. To do 
this, we reviewed the statutes, rules, and statements of policies from 
 
 90. The two-day conference connected state leaders with experts to jump-start improved 
oversight of psychotropic medications. Because Minds Matter: Collaborating to Strengthen 
Management of Psychotropic Medications for Children and Youth in Foster Care, Child Welfare 
Info. Gateway, https://www.childwelfare.gov/systemwide/mentalhealth/effectiveness/mindsmatter.pdf 
(last visited Aug. 1, 2014). 
 91. Some states introduced legislation and regulations to implement provisions of the FCA and 
CFSIIA. California was one of the only states to introduce legislation requiring a plan to improve 
oversight and coordination of healthcare for children in foster care. Cal Welf. & Inst. Code § 16010.2 
(West 2010) (“The [State Department of Social Services], in consultation with pediatricians, other health 
care experts . . . and experts in and recipients of child welfare services, including parents, shall develop a 
plan for the ongoing oversight and coordination of health care services for a child in a foster care 
placement . . . . consistent with . . . [the FCA].”). 
 92. Brian A. ex rel. Brooks v. Sundquist, 149 F. Supp. 2d 941, 944 (M.D. Tenn. 2000). 
 93. Modified Settlement Agreement at 17–18, Brian A. ex rel. Brooks v. Sundquist, 149 F. Supp. 
2d 941 (M.D. Tenn. 2000) (No. 3:00-CV-00445). 
 94. See, e.g., Leslie et al. supra note 11, at 4. 
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sixteen states, representing almost seventy percent of the children in 
foster care in the United States.95 
This review revealed two surprising discoveries: First, we could not 
locate many of the policies reported in other studies, meaning that the 
policies were neither broadly available nor the product of the formal 
rulemaking process in which the final policy would be published. Second, 
to the extent that policies did exist, they were extremely underdeveloped 
and failed to include many of the “red flag” criteria that both experts and 
states identified as essential to protecting children, such as the use of 
psychotropic medications for young children, dosage level, and whether 
multiple psychotropic medications were prescribed simultaneously.96 Our 
detailed findings are available in Appendix A. 
We review the higlights of our findings here. Only Illinois and Texas 
had policies that incorporated all three red flag criteria97 in addition to a 
child welfare prior authorization policy.98 One state, Michigan, addressed 
 
 95. To conduct this research, we reviewed laws, rules and policies available through two sources: 
(1) LexisNexis’s legal database of state legal information and (2) state agency, legislative, and 
regulatory websites. State websites do not generally include archived materials, and we were thus 
confined to the materials available at the time of our searches. For each state, we searched laws and 
rules using LexisNexis which generally included materials from the 1990s through mid-2011. We 
initiated our search using keywords and phrases to search the state’s statutes and code of regulations. 
We recorded the number of non-unique hits in LexisNexis, conducting a preliminary assessment of the 
relevance of our findings. For instance, in some states, adult residential treatment is also termed 
“foster care.” We tried to eliminate those types of erroneous results when recording numbers of hits. 
The number of relevant, but non-unique hits varied for each term, from zero in some states to over 
two dozen in other states. We sorted the laws, rules, and policies into a priori categories, capturing the 
varying types of monitoring policies that could be implemented. 
 96. See Leslie et al., supra note 11, at 7 tbl.1. Other efforts have also reported the status of policies 
in states related to psychotropic medications and children on Medicaid and/or in the child welfare system. 
See, e.g., Mackie et al., supra note 11, at 2215, 2216–18. In 2010, Medicaid and Mental Health State 
Agency Directors published a sixteen-state survey of antipsychotic medication use in Medicaid children 
and adolescents. See generally Medicaid Med. Dirs. Learning Network, supra note 12. And in 2011, a 
report by the GAO examined psychotropic policies for children in six states. See generally U.S. Gov’t 
Accountability Office, GAO-12-201, Foster Children: HHS Guidance Could Help States Improve 
Oversight of Psychotropic Prescriptions (2011) (finding that each of the six states had adopted at least 
one policy, though there was variability across the states). In order to identify the state policies, the GAO 
interviewed officials from the Center for Medicare and Medicaid Services, the Administration for 
Children and Families, state Medicaid agencies, and state foster care agencies. Id. at 4. Additionally, the 
GAO reviewed relevant state policies and regulations. Id. 
 97. In addition to prior authorization, we identify red flags as policies related to psychotropic 
medications for young children, dosage limitations, and restrictions around polypharmacy. See Leslie 
et al., supra note 11, at 7 tbl.1; see also supra notes 11–17 and accompanying text for a more extensive 
discussion of these categories. 
 98. Illinois’ prior authorization regulation was found in the administrative code. Ill. Admin. Code 
tit. 89, § 325.60 (2012). Other regulations are similarly codified. The prior authorization policy is identified 
at Ill. Admin. Code tit. 89, § 325.40 (2012). Additional parameters around prescribing are located at Ill. 
Admin. Code tit. 89, § 325 app. A (2012) (“Guidelines for the Utilization of Psychotropic Medications for 
Children in Foster Care”). Texas’ prior authorization regulation was found in the administrative code at 
40 Tex. Admin. Code § 748.2001 (2007). Texas’s policies are described in a policy document. See 
J - Noonan_19 (E. GOLDBERG).DOC (Do Not Delete) 8/17/2014 4:55 PM 
1534 HASTINGS LAW JOURNAL [Vol. 65:1515 
all three red flag criteria.99 New York and Tennessee address two of the 
red flags.100 Tennessee’s policies are likely the result of the lawsuit 
described above. The remaining three states with policies—Arizona, 
Florida, and Massachusetts—address either one of the red flag criterion 
or had a prior authorization policy.101 Interestingly, most of the policies 
we identified were informally promulgated, meaning that there was no 
notice and comment period and the statements did not have the force of 
law. None of the policies related to dosage levels or age of the child were 
formally promulgated through a notice and comment rulemaking 
 
generally Tex. Dep’t of Family & Protective Servs. & Univ. of Tex. at Austin Coll. of Pharmacy, 
Psychotropic Medication Utilization Parameters for Foster Children (2010). 
 99. Michigan’s policies are evident in a form that lists out criteria triggering further review. That 
form is no longer publicly available. Mich. Dep’t of Human Servs., Foster Care Psychotropic 
Medication Reporting Form, DHS 0674 (on file with authors). 
 100. New York’s policies on the child’s age and polypharmacy can be found in an agency bulletin. 
See N.Y. State Office of Children & Family Servs., No. 08-OCFS-INF-02, Informational Letter 
(2008), available at http://onlineresources.wnylc.net/pb/docs/08-ocfs-inf-02.pdf (“[T]his Informational 
letter . . . provide[s] guidance on the safe and appropriate use of psychiatric medications for children 
and youth in the custody of [Office of Children and Family Services], local social services district 
commissioners or voluntary agencies who have been placed in an out-of-home setting.”). Tennessee’s 
dosage policy states: 
Medication dosages should be kept within FDA guidelines (when available). The clinical 
wisdom, “start low and go slow” is particularly relevant when treating children in order to 
minimize side effects and to observe for therapeutic effects. Any deviations from FDA 
guidelines should be supported by an explanation from the prescribing clinician and may 
warrant review by a [Department of Children’s Services (“DCS”)] consultant. 
Unconventional treatments should be avoided. Medications that have more data regarding 
safety and efficacy are preferred over newly FDA-approved medications. 
State of Tenn. Dep’t of Children’s Servs., Provider Policy Manual 2006–2007, at 94 (2007). 
Tennessee also addressed polypharmacy through policy: “A child on more than three psychotropic 
medications should be supported by an explanation from the prescribing clinician and may warrant 
review by a DCS consultant.” Id. “Anecdotally the prescribing of multiple psychotropic medications 
(combined treatment or polypharmacy) in the pediatric population seems on the increase. Little data 
exist to support advantageous efficacy for drug combinations, used primarily to treat co-morbid 
conditions. The current clinical best practice supports judicial use of combined medications, keeping 
such use to clearly justifiable circumstances.” Id. 
 101. In 2010, the Arizona Department of Health Services issued a guidance document requiring 
documentation for the prescription of multiple psychotropic medications, specifically describing the 
rationale and justification for the combined use. Cenpatico Behavioral Health of Ariz., Provider 
Manual: Psychotropic Medication: Prescribing and Monitoring 3.15.7-E (2010). Also in 2010, the 
Florida Department of Children and Families adopted a policy where a child psychiatrist must be 
retained before a prescribing practitioner may give two or more psychotropic medications to any child 
under the age of eleven in the custody of the Department and in out-of-home care. Brevard Family 
P’ship, Policy & Procedure Manual: Pre-Consent Review for Psychotropic Medication 
Treatment Plans for Children Under Eleven Years of Age in Out-of-Home Care Who Are 
Prescribed Two or More Psychotropic Medications 3 (2012). In 2008, Massachusetts adopted a 
regulation requiring placement agencies to seek judicial approval prior to administering antipsychotic 
medication to youths. 102 Mass. Code Regs. 5.08(5) (2008). 
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procedure.102 Nor were any of the seven policies related to polypharmacy 
formally codified.103 Interestingly, the six states that had prior 
authorization policies promulgated the policies pursuant to formal 
rulemaking.104 
What was most significant about what we found was not that states 
had no policies at all. Rather, it was that, with the exception of prior 
authorization policies, the majority failed to reflect rule of law values 
that should be built into the monitoring of something as important as the 
use of psychotropic medications for children in state foster care custody. 
The next Part of this Article explains rule of law values and describes 
how they can be applied to produce greater transparency in the 
development of policies on monitoring the use of psychotropic 
medications in the child welfare system. 
III.  Transparency and Agency Policymaking 
Under most state rulemaking processes, administrative agencies, 
including child welfare agencies, are permitted to use different types of 
rules, policies, and guidance to interpret and enforce state laws.105 The 
most formal approach is through legislative rulemaking, which is similar 
to legislation created by the legislative branches. Legislative rules are 
legally binding, subject to public notice and comment, and may result in 
criminal or civil penalties if violated.106 Alternatively, interpretive rules 
interpret an agency’s position or understanding of an existing statute or 
regulation and are not intended to be legally binding, which is why many 
 
 102. States with policies around psychotropic medications for young children were: Illinois, 
Michigan, New York, and Texas. States with dosage policies were Illinois, Michigan, Tennessee, and 
Texas. See infra Appendix A for citations to these policies. 
 103. Polypharmacy is generally understood to be the use of multiple medications. However, exact 
definitions vary. For the purposes of this study, we used a broad definition simply meaning any policy 
a state enacted that addressed some type of use of multiple medications. The states in which we 
identified a policy related to polypharmacy were Arizona, Florida, Illinois, Michigan, New York, 
Tennessee, and Texas. See infra Appendix A. 
 104. The states in which we identified a rule related to prior authorization were: Arizona, California, 
Florida, Illinois, Massachusetts, and Texas. See Ariz. Admin. Code § 21-206.01 (2003); Cal. Code Regs. 
tit. 22, § 89475 (2010); Fla. Admin. Code Ann. r. 65C-35.010 (2010); Ill. Admin. Code tit. 89, § 325.60 
(2012); 102 Mass. Code Regs. 5.08(5) (2008); 40 Tex. Admin. Code § 748.2001 (2007). 
 105. See generally Todd D. Rakoff, The Choice Between Formal and Informal Modes of Administrative 
Regulation, 52 Admin L. Rev. 159 (2000) (providing a broad overview of the different ways administrative 
agencies issue regulations and decisions); see also Levin, supra note 18, at 858–84 (discussing administrative 
rules and guidance documents under the 2010 MSAPA); Michael Asimow, Guidance Documents in the 
States: Toward a Safe Harbor, 54 Admin. L. Rev. 631, 632–33 (2002) (discussing the differences in adoption 
procedures for guidance documents and formal administrative rules).  
 106. See Peter L. Strauss, The Place of Agencies in Government: Separation of Powers and the 
Fourth Branch, 84 Colum. L. Rev. 573, 576 (1984) (“Validly adopted legislative rules are identical to 
statutes in their impact on all relevant legal actors—those subject to their constraints . . . and judges or 
others who may have occasion to consider them in the course of their activities.”). 
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states do not require notice and comment for this type of rule.107 Finally, 
agencies may issue guidance documents in the form of interpretive rules 
or policy statements that, in most states, are not subject to notice and 
comment and are not intended to be legally binding.  
One key feature of formal policymaking is transparency.108 
Transparency requires government institutions to be accountable, visible, 
and accessible to the public.109 One of the most fundamental ways to 
promote external observation and make agencies more accountable to 
the public is through public disclosures.110 “[R]egulations should be 
written to maximize consumers’ ability to understand their most 
important features . . . and to evaluate the relative advantages and 
disadvantages of the system vis à vis competitive systems.”111 This need is 
“more true where consumers need to evaluate the range of risks” 
associated with a given regulation.112 The range of risks from excessive 
use of psychotropics is extensive.113 The large array of stakeholders 
involved in the child welfare system magnifies the need for transparency. 
When the rulemaking process proceeds without transparency, the 
public’s ability to participate is dramatically undercut.114 Lacking an 
understanding of the basic rationale behind a regulation, the public 
cannot be expected to scrutinize or understand the rule in a meaningful 
way.115 This has a number of disadvantages. “Lack of transparency can 
be costly both politically and economically. It is politically debilitating 
because it dilutes the ability of the democratic system to judge and 
correct government policy by cloaking the activities of special interests 
and because it creates [disparities] by giving those with information 
something to trade.”116 
 
 107. Administrative Procedure Act, 5 U.S.C. §§ 551–559 (2006). 
 108. See Thomas O. Sargentich, The Reform of the American Administrative Process: The 
Contemporary Debate, 1984 Wis. L. Rev. 385, 406 (1984). (“[A]gencies [must] take a hard look at the 
underpinnings of their decision and provide a sufficient explanation of the reasons for their ultimate 
choice . . . .”). 
 109. Mark Fenster, Seeing the State: Transparency As Metaphor, 62 Admin. L. Rev. 617, 619–20 (2010). 
 110. See Doe v. Reed, 130 S. Ct. 2811, 2820 (2010) (discussing how important public disclosures 
are to creating governmental transparency, particularly in the case of elections). 
 111. See Hughes, supra note 23, at 832 (discussing benefits of transparency in relation to consumer 
cyberpayment options). 
 112. See id. 
 113. See supra notes 67–72 and accompanying text for a discussion of the side effects and other 
risks of psychotropic medication use in children. 
 114. John D. Graham, Saving Lives Through Administrative Law and Economics, 157 U. Pa. L. 
Rev. 395, 442 (2008). 
 115. Id. 
 116. John M. Ackerman & Irma E. Sandoval-Ballesteros, The Global Explosion of Freedom of 
Information Laws, 58 Admin. L. Rev. 85, 93 (2006) (citing Daniel Kaufmann & Tara Vishwanath, 
Toward Transparency: New Approaches and Their Application to Financial Markets, 16 World Bank 
Res. Observer 41, 44 (2001)). 
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Within the context of formal policymaking, transparency typically 
involves a public notice and comment period, during which experts and 
the public at large can give feedback to the relevant agency on a 
proposed course of action.117 While agencies typically have no obligation 
to follow any particular course of commentary, such commentary can 
lead to better policy outcomes.118 Formal, publicly available rules can 
ensure consistency in approaches to treatment that can result in long-
term efficiencies for practitioners and perhaps better outcomes for 
children subject to those rules. This will, of course, depend on the quality 
of the rule in the first place. Because problematic formal rules can be 
more effectively challenged in judicial proceedings ex post their fate and 
durability will also generally be a matter of public record. Public 
discourse surrounding the litigation of a disputed rule can, itself, 
heighten awareness of the underlying problem, making improved 
rulemaking more plausible.119 
Some scholars argue that agencies need flexibility in their day-to-
day management responsibilities and that the formal policymaking 
process is neither efficient nor realistic given the scope of issues that 
require agency policymaking.120 To be sure, formal policymaking can add 
months or years to the articulation of agency policy. Informal 
policymaking also offers flexibility generally unavailable in formal 
policymaking, allowing agencies to function more smoothly.  
Scholars have wrestled with the tension between the costs and 
benefits of informal agency policymaking.121 Some of the debate focuses 
on whether judicial review of agency policies—whether they have been 
promulgated formally or informally—should be ex ante or ex post. More 
recently, scholars have tried to change the discussion from how courts 
decide whether a policy is formal or informal to requiring agencies to 
justify their choice of policy mechanism up front. For example, M. 
Elizabeth Magill has proposed that agencies should be required to justify 
their choice and the factors they considered in coming to their 
decision.122 Nina A. Mendelson has proposed instead that Congress 
amend the federal APA to allow stakeholders to petition agencies to 
amend or repeal informal policies.123 Mark Seidenfeld, by contrast, 
 
 117. Rakoff, supra note 105, at 163–64. 
 118. See Fenster, supra note 109, at 619–20 (noting that in order for government institutions to be 
held accountable and perform well, the institution must be visible to external observation; in other 
words, it must be transparent). 
 119. See M. Elizabeth Magill, Agency Choice of Policymaking Form, 71 U. Chi. L. Rev. 1383, 1391 
(2004) (noting that most formal administrative adjudication involves a “trial-like hearing”). 
 120. See Strauss, supra note 106, at 595, 666. 
 121. See Seidenfeld, supra note 23, at 364–66. 
 122. Id. 
 123. Nina A. Mendelson, Regulatory Beneficiaries and Informal Agency Policymaking, 
92 Cornell L. Rev. 397, 438 (2007). 
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contends that the proposals suggested by Magill and Mendelson would 
“bog down the issuance of guidance documents.” He instead advocates 
for “reasoned decisionmaking” through which agencies justify their 
policy in light of their consequences, which he argues would urge 
agencies to consider outflows from their policymaking more clearly.124 
Finally, it is worth noting that states face distinct challenges in 
administrative rulemaking as compared to those faced by the federal 
government. First, most states tend to have less rigorous standards for 
formal policymaking. Within federal agencies, for example, a rule may be 
found invalid if it is determined to be “arbitrary and capricious” and not 
rationally related to the content of the legislation it is meant to 
interpret.125 For states, the standard of judicial review often varies from 
the federal standard in terms of both the deference given agencies and 
the analysis of reviewable rules.126 Similarly, while federal policymaking 
standards have been broadly litigated and spawned much analysis, many 
states have not had a comparable level of judicial review and public 
wrestling with state standards. Second, and perhaps more importantly, 
states have far more limited resources at their disposal for policymaking 
than federal agencies.127 This may be more acute for state human services 
agencies like child welfare, which is historically underfunded and lacks 
significant investment in human capital. 
IV.  State Policymaking on Psychotropic Medications for 
Children in Foster Care 
The issue of high rates of psychotropic medication use by children in 
foster care has been festering for years. The federal government, as well 
as media and professional associations, recently began to bring attention 
to the need for improved monitoring of psychotropic medications.128 Yet, 
 
 124. Seidenfeld, supra note 23, at 367, 373–75. 
 125. See, e.g., Motor Vehicle Mfrs. Ass’n v. State Farm Mut. Auto. Ins. Co., 463 U.S. 29, 39–40 
(1983). 
 126.  See, e.g., Bernard W. Bell, The Model APA and the Scope of Judicial Review: Importing 
Chevron into State Administrative Law, 20 Widener L.J. 801, 804–05 (2011) (discussing Oregon’s 
judicial review standards and grouping of statutory terms into three categories: “terms of precise 
meaning,” “inexact terms,” and “terms of delegation”); see also Arthur Earl Bonfield, The Federal 
APA and State Administrative Law, 72 Va. L. Rev. 297, 336 (1986) (“Differences between the details 
of state administrative law and the federal APA on other subjects—such as adjudication and judicial 
review—are as numerous and significant as those just noted in the rulemaking context.”). 
 127. See Jeffrey M. Hirsch, Taking States Out of the Workplace, Yale L.J. F. (Apr. 3, 2008), 
http://www.yalelawjournal.org/forum/taking-states-out-of-the-workplace (“Most state policymakers 
lack the time, resources, and expertise of their federal counterparts.”). 
 128. See supra notes 6, 37, 59 for the GAO reports relevant to oversight of psychotropic 
medications and foster care. The media has also covered the use of psychotropic medication in 
children in foster care. See, e.g., Ana M. Valdes, Psychotropic Drug Use Higher for Foster Kids; a 
Five-State Study that Includes Florida Shows a Wide Disparity, Palm Beach Post, Dec. 2, 2011, at A1; 
Doctors Put Foster Children at Risk with Mind-Altering Drugs (ABC television broadcast Dec. 1, 
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states have been slow to implement policies or document significant 
decreases in prescribing rates. There could be many reasons for this slow 
movement toward change, including the lack of alternative non-
pharmacological therapeutic interventions, the disconnect between child 
welfare systems and the healthcare providers who serve children in foster 
care, and the lack of internal health experts in child welfare systems.129 
Based on our review, the majority of policies implemented by states 
regarding oversight of psychotropic medications for children in foster 
care have been issued informally, which means they have been subject to 
little, if any, public discourse or scrutiny, and are non-binding, which 
means that recourse for non-compliance is more limited.130 Our review of 
psychotropic medication policies for children in foster care revealed 
another weakness of using informal policy: the inability to verify agency 
guidance documents, since most states we reviewed do not make their 
documents available through their websites or other public databases. 
Thus, a possible explanation for the differences in reported results in our 
study compared to earlier studies could be that the key informants 
interviewed had access to policies that were not publicly available, or at 
least easily publicly accessible. This also reveals an inherent weakness in 
studies that rely on key informant interviews as a core source of data 
related to policy: the informants’ statements are not always verifiable 
through public searches of published policy statements, meaning the 
public may not be able to access the policies, or they may be largely 
unknown outside of certain segments of a specific agency. This is an 
important contrast to formal policies, which are codified in statutes or 
regulations that are publicly accessible. 
We do not mean to suggest that the findings from our review should 
be read as contradicting earlier studies. Those studies capture an 
important policy reality at the state agency executive level that could, in 
fact, be closer to the norm. But, in the absence of a formal promulgation 
process, it is difficult to know whether stakeholders other than those at 
the state agency had a chance to comment on, or are even aware of, the 
policy. More importantly, it is difficult to understand what recourse, if 
any, is available if the policy is not followed. 
 
2011), available at http://abcnews.go.com/Health/doctors-put-foster-children-risk-mind-altering-
drugs/story?id=15064560; Foster Kids Prescribed Psychotropic Drugs (ABC television broadcast 
Dec. 2, 2011), available at http://abcnews.go.com/2020/video/foster-kids-prescribed-psychotropic-
drugs-heavy-duty-drug-treatments-neglect-2020-15077792. 
 129. See Camp, supra note 4, at 373–75, 382–88, 397–401 (describing both the disconnect between 
mental health and healthcare in foster care, as well as the reimbursement incentives for continued 
medication use). 
 130. See supra notes 18–21 and accompanying text for information about informal policy making; 
see also Appendix B, infra, for various state definitions of informal policy making and whether those 
states require a notice and comment period for informally adopted policies and rules.  
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Transparency is not, however, without its costs.131 In the context of 
child welfare, there is a presumption that sensitive information about or 
pertaining to minors should remain confidential.132 Also, matters 
involving the healthcare of children must include zones of discretion, 
whereby qualified professionals may exercise judgment about 
appropriate courses of action unburdened by concerns of being second-
guessed by bureaucracies unfamiliar with or indifferent to the particulars 
of the case at hand. Nevertheless, we concur with the scholars who 
advocate more responsibility on the part of agencies to make their 
reasoning with regard to policymaking transparent. The vast disparity in 
prescription rates between children in and out of foster care custody 
remains cause for concern. Some type of “reasoned decisionmaking” 
should be required with regard to psychotropic medications so that 
agencies are intentional and up front about their use of informal versus 
formal policy. 
In furtherance of the 2008 FCA and the 2011 CFSIIA, the CB 
decided in 2012 that it would require states to issue “protocols for the 
appropriate use and monitoring of psychotropic medications.”133 These 
protocols would, among other things, govern assessment, individual 
medication decisionmaking (such as consent), communication between 
stakeholders, and sharing information related to psychotropic 
prescriptions among clinicians, child welfare staff, and consumers.134 
While this sounds like a step toward transparency, it is not sufficient 
because, as our study has shown, the mere fact that a state should have 
policies about prescribing psychotropic medications to children does not 
guarantee that those policies themselves will be formalized or publicly 
available. It is therefore incumbent on the federal government and state 
child welfare agencies to determine the most effective mechanisms for 
monitoring this issue, and making monitoring policies broadly known. 
Conclusion 
Our review found that few state child welfare agencies within our 
study period had publicly available, comprehensive policies addressing 
psychotropic medication prescriptions for children in foster care. To the 
 
 131. See supra notes 109–16 and accompanying text for a discussion of the advantages and 
disadvantages of providing transparency in the administrative rulemaking process. 
 132. See generally Confidentiality in Public Child Welfare: Frequently Asked Questions, Nat’l Ass’n of 
Pub. Child Welfare Adm’rs, http://www.duluth.umn.edu/sw/cw/lowo/tabs/4/ConfidentialityFAQs.pdf (last 
visited Aug. 1, 2014) (providing a broad overview of the confidentiality practices related to child welfare). 
The tension between transparency and privacy is evident as child welfare systems consider reform. See Erik 
Schelzig, Tennessee Fights Transparency for Child Welfare Agency, The Daily News (Jan. 8, 2013), 
http://www.memphisdailynews.com/news/2013/jan/8/tennessee-fights-transparency-for-child-welfare-agency. 
 133. See Information memorandum 12-03, supra note 8, at 1. 
 134. Id. at 12–13. 
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extent policies did exist, they were informal, were not developed through 
a public notice and comment process, and had little, if any, redress 
available if the policies were not followed. What this means is that in 
many states, policymakers, providers, families, children and youth, and 
citizens have little information about psychotropic medication policies 
specifically regarding monitoring for children in foster care. Without 
such information, it is difficult to understand and assess the ability of 
individual states to oversee psychotropic medications. Moreover, as long 
as practice is so distinct from publicly accessible requirements, states will 
face challenges in implementing and demonstrating adherence to federal 
or more local requirements. Equally important, states may also confront 
challenges in coordinating services between agencies and in identifying 
promising practices for the challenging task of overseeing psychotropic 
medication use by children in foster care. 
The newly articulated federal guidelines for child welfare agencies 
related to psychotropic medications provide states with a starting point 
for reassessing their approach to psychotropic medication oversight. But 
they are only a starting point. State child welfare agencies presently have 
the opportunity to implement reforms and make those reforms publicly 
accessible. This Article seeks to encourage states to do so and to 
thoughtfully consider the purpose of oversight measures and the need for 
broad dissemination of promulgated policies that provide for stakeholder 
participation, ratification, and process for redress where non-compliance 
occurs. 
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Appendix A: State Approaches to Monitoring 




AZ None None Yes (2010) (P)i  Yes (2003) (R)ii 
CA None None None Yes (2010) (R)iii 
FL None None Yes (2010) (P)iv Yes (2010) (R)v 
GA None None None None 
IL Yes (2008) (P)vi  Yes (2008) (P)vii  Yes (2008) (P)viii  Yes (1995) (R)ix 
KY None  None None  None 
MA None None None Yes (2008) (R)x 
MD None  None None None 
MI Yes (2011) (P)xi  Yes (2011) (P)xii  Yes (2011) (P)xiii  None 
NC None None None None 
NY Yes (2008) (P)xiv  None Yes (2008) (P)xv  None 
OH None None None None 
PA None None None None 
TN None Yes (2007) (P)xvi  Yes (2007) (P)xvii  None 
TX Yes (2010) (P)xviii  Yes (2010) (P)xix  Yes (2010) (P)xx  Yes (2007) (R)xxi 
VA None None None None 
(P) Informal guidance document, including policy statements and interpretive rules.  
(R) Formal legislative regulation, adopted in compliance with state APA requirements. 
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Legislative Rules Defined 
(“Formal Policy”) 
Policy Document / 






 46 61 81 10    
AZxxii  X X  An agency statement of general 
applicability that implements, 
interprets or prescribes law or 
policy, or describes the 
procedure or practice 
requirements of an agency. 
Rules include prescribing fees 
or the amendment or repeal of 
a prior rule but do not include 
intraagency memoranda that 
are not delegation agreements. 
A written expression that 
informs the general public 
of an agency's current 
approach to, or opinion of, 
the requirements of the 
federal or state 
constitution, federal or 
state statute, administrative 
rule or regulation, or final 
judgment of a court of 
competent jurisdiction, 
including, where 
appropriate, the agency's 
current practice, procedure 
or method of action based 
upon that approach or 
opinion. 
No. xxiii 
CAxxiv X  X  Every rule, regulation, order, or 
standard of general application 
or the amendment, supplement, 
or revision of any rule, 
regulation, order, or standard 
adopted by any state agency to 
implement, interpret, or make 
specific the law enforced or 
administered by it, or to govern 
its procedure. 
Any guideline, criterion, 
bulletin, manual, 
instruction, order, standard 
of general application, or 
other rule, unless the 
guideline, criterion, 
bulletin, manual, 
instruction, order, standard 
of general application, or 
other rule has been adopted 
as a regulation and filed 
with the Secretary of State. 
Yes. xxv 
FLxxvi  X X  Each agency statement of 
general applicability that 
implements, interprets, or 
prescribes law or policy or 
Internal management 
memoranda that do not 
affect either the private 
interests of any person or 
No. xxvii 
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describes the procedure or 
practice requirements of an 
agency and includes any form 
that imposes any requirement 
or solicits any information not 
specifically required by statute 
or by an existing rule.  
any plan or procedure 
important to the public and 
which have no application 
outside the agency issuing 
the memorandum. 
GAxxviii  X   Each agency regulation, 
standard, or statement of 
general applicability that 
implements, interprets, or 
prescribes law or policy or 
describes the organization, 
procedure, or practice 
requirements of any agency. 
Statements concerning only 
the internal management of 
an agency and not affecting 
private rights or procedures 
available to the public; 
declaratory rulings; intra-
agency memoranda; 
statements of policy or 
interpretations that are 
made in the decision of a 
contested case.xxix 
No. xxx 
ILxxxi X X   Each agency statement of 
general applicability that 
implements, applies, interprets, 
or prescribes law or policy. 
Statements concerning 
only the internal 
management of an agency 
and not affecting private 
rights or procedures 
available to persons or 
entities outside the agency, 
informal advisory rulings 
issued under Section 5-150, 
intra-agency memoranda, 
or guidance documents 
prepared by IEPA. 
No. xxxii 
KYxxxiii     Each statement of general 
applicability promulgated by an 
administrative body that 
implements, interprets, or 
prescribes law or policy, or 
describes the organization, 
procedure, or practice 
requirements of any 
administrative body. 
Statements concerning only 
the internal management of 
an administrative body and 
not affecting the private 
rights or procedures to the 
public; declaratory rulings; 
and intradepartmental 
memoranda not in conflict 
with KRS 13A. 130.xxxiv 
Yes. xxxv 
MAxxxvi   X  The whole or any part of every 
rule, regulation, standard or 
other requirement of general 
application and future effect, 
Advisory rulings issued 
under section eight; or 
regulations concerning only 
the internal management or 
No. xxxviii 
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including the amendment or 
repeal thereof, adopted by an 
agency to implement or 
interpret the law enforced or 
administered by it, but does not 
include advisory rulings or 
regulations concerning internal 
management.  
discipline of the adopting 
agency or any other agency, 
and not substantially 
affecting the rights of or the 
procedures available to the 
public or that portion of the 
public affected by the 
agency’s activities.xxxvii 
MDxxxix  X   A statement or an amendment 
or repeal of a statement that 
has general application; has 
future effect; is adopted by an 
officer or unit authorized by 
law to adopt regulations, 
govern organization of the unit, 
govern the procedure of the 
unit, govern practice before the 
unit; and is in any form, 
including a guideline, a rule, a 
statement of interpretation, or 
a statement of policy. 
A statement that concerns 
only internal management 
of the unit and does not 
affect the rights of the 
public or the procedures 
available to them directly, 
or a declaratory ruling of 
the unit as to a regulation. 
Yes. xl 
MIxli X    An agency regulation, 
statement, standard, policy, 
ruling, or instruction of general 
applicability that implements or 
applies law enforced or 
administered by the agency, or 
that prescribes the 
organization, procedure, or 
practice of the agency, 
including the amendment, 
suspension, or rescission of the 
law enforced or administered 
by the agency. 
An intergovernmental, 
interagency, or intraagency 
memorandum, directive, or 
communication that does 
not affect the rights of, or 
procedures and practices 
available to, the public. A 
form with instructions, an 
interpretive statement, a 
guideline, an informational 
pamphlet, or other material 
that does not have the force 
and effect of law but is 
merely explanatory. 
No. xlii 
NCxliii X X   Any agency regulation, 
standard, or statement of 
general applicability that 
implements or interprets an 
enactment of the General 
Assembly or Congress or a 
regulation adopted by a federal 
agency or that describes the 
Nonbinding interpretative 
statements within the 
delegated authority of an 
agency that merely define, 
interpret, or explain the 
meaning of a statute or 
rule. Statements of agency 
policy made in the context 
No. xliv 
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procedure or practice 
requirements of an agency. The 
term includes the establishment 
of a fee and the amendment or 
repeal of a prior rule. 
of another proceeding. 
 
NYxlv  X   The whole or part of each 
agency statement, regulation or 
code of general applicability 
that implements or applies law, 
or prescribes a fee charged by 
or paid to any agency or the 
procedure or practice 
requirements of any agency, 
including the amendment, 
suspension or repeal thereof. 
Forms and instructions, 
interpretive statements, and 
statements of general policy 
that, in themselves, have no 
legal effect but are merely 
explanatory. 
No. xlvi 
OHxlvii X    Any rule, regulation, or 
standard, having a general and 
uniform operation, adopted, 
promulgated, and enforced by 
any agency under the authority 
of the laws governing such 
agency, and includes any 
appendix to a rule. 
Any internal management 
rule of an agency. 
Yes. xlviii 
PAxlix X   Xl Any regulation except a 
proclamation, executive order, 
executive directive, or other 
similar document promulgated 
by the Governor. The term 
includes a regulation that may 
be promulgated by an agency 
only with the approval of the 
Governor. 
Any document, except an 
adjudication or a 
regulation, promulgated by 
an agency, which sets forth 
substantive or procedural 
personal or property rights, 
privileges, immunities, 
duties, liabilities or 
obligations of the public or 
any part thereof, and 
includes, any document 
interpreting or 
implementing any act of 
Assembly enforced or 
administered by such 
agency. 
No. li 
TNlii X  X  Each agency statement of 
general applicability that 
implements or prescribes law or 
policy or describes the 
Intraagency memoranda; 
general policy statements 
that are substantially 
repetitious of existing law. 
No. liii 
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procedures of any agency. “Policy” means a set of 
decisions, procedures, and 
practices pertaining to the 
internal operation or 
actions of an agency. 
TXliv     A state agency statement of 
general applicability that: 
implements, interprets, or 
prescribes law or policy or 
describes the procedure or 
practice requirements of a state 
agency. 
A statement regarding only 
the internal management or 
organization of a state 
agency and that does not 
affect private rights or 
procedures. 
No. lv 
VAlvi X    Any statement of general 
application, having the force of 
law, affecting the rights or 
conduct of any person, adopted 
by an agency in accordance 
with the authority conferred on 
it by applicable basic laws. 
Any document developed 
by a state agency or staff 
that provides information 
or guidance of general 
applicability to the staff or 
public to interpret or 
implement statutes or the 
agency's rules or 
regulations. 
No. lvii 
                                                          
 i Provider manuals were created from templates issued by the Arizona Department of Health 
Services, Division of Behavioral Health Services. See, e.g., Cenpatico Behavioral Health of Ariz., 
Provider Manual: Psychotropic Medication: Prescribing and Monitoring 3.15.7-E (2010).  
 ii Ariz. Admin. Code § R9-21-206.01 (2003). 
 iii Cal. Code Regs. tit. 22, § 89475 (2010). 
 iv State of Fla. Dep’t of Children and Families, Pre-Consent Review for Psychotropic 
Medication Treatment Plans for Children Under Eleven (11) Years of Age in Out-of-Home 
Care Who are Prescribed Two (2) or More Psychotropic Medications (2010), available at 
http://centerforchildwelfare2.fmhi.usf.edu/kb/DCF_Pol/Family%20Safety%20CFOP's/CFOP175-98Pre-
ConsentReview.pdf.  
 v Fla. Admin. Code Ann. r. 65C-35.010 (2010).  
 vi Factors that trigger case review include a heightened level of medications for children six or 
younger, or the presence of any non-stimulant medication for children under four years old. See Ill. 
Admin. Code tit. 89, § 325 app. A (2012) (“Guidelines for the Utilization of Psychotropic Medications 
for Children in Foster Care”).  
 vii Id. § 325.40. 
 viii There are additional parameters around polypharmacy prescriptions. Id. § 325 app. A. 
 ix An administrative rule requires prior approval from an authorized agent before a physician 
can prescribe a psychotropic medication to any child for whom the department is legally responsible. 
Id. § 325.60.  
 x 102 Mass. Code Regs. 5.08(5) (2008). 
 xi See Mich. Dep’t of Human Servs., Form DHS-1643: Psychotropic Medication Informed 
Consent (2014) (on file with authors). 
 xii See id. 
 xiii See id. 
 xiv See generally N.Y. State Office of Children & Family Servs., supra note 100.  
 xv Id. at 11–13. 
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 xvi State of Tenn. Dep’t of Children’s Servs., supra note 100, at 94.  
 xvii Id.  
 xviii See generally Tex. Dep’t of Family & Protective Servs. & Univ. of Tex. at Austin Coll. of 
Pharmacy, supra note 98. 
 xix Id. at 12–18. 
 xx Id. at 4, 8. 
 xxi 40 Tex. Admin. Code § 748.2001 (2007). 
 xxii Ariz. Rev. Stat. Ann. § 41-1001 (2013). 
 xxiii Asimow, supra note 105, at 642 n.53 (noting that Arizona’s broad definition of “substantive 
policy statement” creates an exception to the normal rulemaking requirements). 
 xxiv Cal. Gov’t Code § 11342.600 (West 2014). 
 xxv Id. § 11340.5. See Asimow, supra note 105, at 644 (“More than any other state, California 
prohibits the adoption of guidance documents without APA compliance and strongly enforces this 
prohibition both through court decisions and an administrative determination mechanism.”). 
 xxvi Fla. Stat. Ann. § 120.52 (2013).  
 xxvii See Asimow, supra note 105, at 641 (noting that Florida construes “rule” in a manner that 
covers only quasi-legislative action that has the force of law, therefore implicitly exempting “guidance 
documents” and other policy statements from the formal public notice and comment period). A 
“policy statement will not be treated as [a] rule because [it is] not intended to create rights or require 
compliance or otherwise to have the direct and consistent effect of law.” Id. at 641 n.45. But see 
Jenkins v. State, 855 So. 2d 1219, 1225 (Fla. Dist. Ct. App. 2003) (“An agency statement or policy is a 
rule if its effect requires compliance, creates certain rights while adversely affecting others, or 
otherwise has the direct and consistent effect of law.”).  
 xxviii Ga. Code Ann. § 50-13-2 (2013); id. § 50-13-4. 
 xxix Id. § 50-13-2.  
 xxx See Asimow, supra note 105, at 642 (Georgia has “adopt[ed] the federal exception for 
interpretive rules and policy statements”). 
 xxxi Ill. Admin. Code. tit. 100, § 1.70 (2012).  
 xxxii See Asimow, supra note 105, at 640 (Illinois has applied the 1961 exception for “intra-agency 
memoranda” to their interpretive rules and guidance documents). See also People v. Carpenter, 895 
N.E.2d 24, 33 (Ill. App. Ct. 2008) (holding that implementations of existing regulations are not subject 
to APA requirements). 
 xxxiii Ky. Rev. Stat. Ann. § 13A.010 (West 2014). 
 xxxiv Id. 
 xxxv Asimow, supra note 105, at 651 (providing “that the term regulation includes manuals, 
policies, instructions, guides to enforcement, interpretive bulletins, interpretations, and the like that 
have the effect of rules, orders, regulations, or standards of general application”). See also Ky. Rev. 
Stat. Ann. § 13A.010 (“An administrative body shall not by internal policy, memorandum, or other 
form of action: modify a statute or administrative regulation; expand upon or limit a statute or 
administrative regulation . . . .”). 
 xxxvi Mass. Gen. Laws ch. 30A, § 1 (2014); id. § 8. 
 xxxvii Id. § 1. 
 xxxviii See Asimow, supra note 105, at 641 (noting that the Massachusetts Supreme Court has held 
“the legislature could not possibly have intended the rulemaking procedure apply to every guidance 
document”). See also Mass. Gen. Hosp. v. Rate Setting Comm’n, 359 N.E.2d 41 (1977) (holding that 
advisory or information pronouncements may be lawfully issued by an agency in relation to a 
regulation or statute without going through the procedures required for promulgation of a regulation). 
 xxxix Md. Code Ann., State Govt § 10-101(G)(1) (West 2014). 
 xl See Asimow, supra note 105, at 641 (noting that Maryland construes “rule” in a manner that 
covers only quasi-legislative action that has the force of law, therefore implicitly exempting “guidance 
documents” and other policy statements from the formal public notice and comment period). Despite 
the language of the statute, which plainly equates rules/regulations with interpretive rules, Asimow 
asserts that Maryland courts have seemingly upheld the legitimacy of policy statements passed without 
notice or comment periods. Id. (citing Dep’t of Health & Mental Hygiene v. Chimes, Inc., 681 A.2d 
484, 488-90 (Md. 1996)). But see Delmarva Power & Light Co. v. Pub. Serv. Comm’n of Md., 370 Md. 
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1, 34, 803 A.2d 460, 479 (2002) (distinguishing Chimes and concluding that agencies may not adopt 
standards that constitute regulations under the APA without complying with APA requirements).  
 xli Mich. Comp. Laws Ann. § 24.207 (2014).  
 xlii See Asimow, supra note 105, at 642 (enacting legislation creating explicit rulemaking 
exceptions for certain guidance documents). 
 xliii N.C. Gen. Stat. § 150B-2 (2014).  
 xliv See Asimow, supra note 105, at 642 (enacting legislation creating explicit rulemaking 
exceptions for certain types of guidance documents). 
 xlv N.Y. Comp. Codes R. & Regs. tit. x, § 102(a) (2014). 
 xlvi See Asimow, supra note 105, at 642 (enacting legislation creating explicit rulemaking 
exceptions for types of certain guidance documents). See also Pharmacists Soc’y, State of N.Y., Inc. v. 
Pataki, 58 A.D.3d 924, 926 (N.Y. App. Div. 2009) (holding that interpretive statements are exempt 
under New York’s APA).  
 xlvii Ohio Rev. Code Ann. § 119.01 (West 2014). 
 xlviii See Asimow, supra note 105, at 638 (noting that Ohio has no functioning exception from the 
notice and comment requirements required of “rules” for guidance documents). 
 xlix 2 Pa. Cons. Stat. Ann. § 101 (West 2007).  
 l Pennsylvania is the only state that has introduced legislation proposing to adopt the 2010 
Revised Model State Administrative Procedure Act. State Administrative Procedure Act, Revised 
Model, Unif. Law Comm’n, http://www.uniformlaws.org/ 
Act.aspx?title=State%20Administrative%20Procedure%20Act,%20Revised%20Model (last visited Aug. 1, 
2014). 
 li See Asimow, supra note 105, at 642 (enacting legislation creating explicit rulemaking 
exceptions for certain guidance documents. See also Success Against All Odds v. Dep’t of Pub. 
Welfare of the Commonwealth of Pa., 700 A.2d 1340 (Pa. Commw. Ct. 1997) (Administrative agency 
may render interpretive law so long as interpretation is one that reviewing court determines is 
consistent with meaning of statute with respect to which it is rendered). For a discussion of how 
Pennyslvania interprets and affords deference to agency rulemaking, see Nw. Youth Servs., Inc. v. 
Commonwealth of Pa., Dep’t of Pub. Welfare, 66 A.3d 301 (Pa. 2013). 
 lii Tenn. Code Ann. § 4-5-102 (2014). 
 liii See Asimow, supra note 105, at 642 (enacting legislation creating explicit rulemaking 
exceptions for certain guidance documents). See also Mandela v. Campbell, 972 S.W.2d 531, 534 
(Tenn. 1998) (noting that “a policy is not a rule under the UAPA if the policy concerns internal 
management of state government and if the policy does not affect the private rights, privileges, or 
procedures available to the public”).  
 liv Tex. Gov’t Code Ann. § 2001.003 (West 2013). 
 lv Brinkley v. Tex. Lottery Comm’n, 986 S.W.2d 764, 769 (Tex. App. 1999) (“If every expression 
by the agency as to ‘law,’ ‘policy,’ and procedural ‘requirements’ requires the promulgation of a formal 
rule, the agency could no longer exercise its “informed discretion” to choose adjudication as a means 
of making law and policy, rather than rulemaking, a choice we have repeatedly said an agency has 
when it possesses both adjudicatory and rulemaking powers.”).  
 lvi Va. Code Ann. § 2.2-4001 (2014). 
 lvii Asimow, supra note 105, at 644 (“Guidance documents need not be adopted with notice and 
comment, but they must be filed with the Registrar for publication. . . .”). See also Davenport v. Summit 
Contractors, Inc., 612 S.E.2d 239, 243 (Va. Ct. App. 2005) (quoting Jackson v. W., 419 S.E.2d 385, 389 
(Va. Ct. App. 1992) (guidance documents are not “subject to the scrutiny associated with promulgated 
regulations, [and therefore] agency guidelines ‘do not purport to be a substitute for the statute’”). 
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